The aim of this study was to determine if an intensive lifestyle intervention (ILI) reduces the severity of obstructive sleep apnea (OSA) in rapid-eye movement (REM) sleep, and to determine if longitudinal changes in glycaemic control are related to changes in OSA severity during REM sleep over a 4-year follow-up. This was a randomized controlled trial including 264 overweight/obese adults with type 2 diabetes (T2D) and OSA. Participants were randomized to an ILI targeted to weight loss or a diabetes support and education (DSE) control group. Measures included anthropometry, apnea-hypopnea index (AHI) during REM sleep (REM-AHI) and non-REM sleep (NREM-AHI) and glycated haemoglobin (HbA1c) at baseline and year 1, year 2 and year 4 follow-ups. Mean baseline values of REM-AHI were significantly higher than NREM-AHI in both groups. Both REM-AHI and NREM-AHI were reduced significantly more in ILI versus DSE, but these differences were attenuated slightly after adjustment for weight changes. Repeated-measure mixed-model analyses including data to year 4 demonstrated that changes in HbA1c were related significantly to changes in weight, but not to changes in REM-AHI and NREM-AHI. Compared to control, the ILI reduced REM-AHI and NREM-AHI during the 4-year follow-up. Weight, as opposed to REM-AHI and NREM-AHI, was related to changes in HbA1c. The findings imply that weight loss from a lifestyle intervention is more important than reductions in AHI for improving glycaemic control in T2D patients with OSA.
various confounding factors (Aronsohn et al., 2010) . OSA may lead to dysregulated glucose metabolism by inducing intermittent hypoxia and excessive sympathetic nervous system activation (Pamidi and Tasali, 2012) .
OSA severity during rapid eye movement (REM) sleep was found to be associated particularly with worsened glycaemic control in T2D patients (Grimaldi et al., 2014) . This may not be surprising, as REM sleep is associated with increased sympathetic nervous system activation (Somers et al., 1993) , longer apnea duration (Findley et al., 1985) and greater hypoxaemia during OSA events versus non-REM (NREM) sleep (Krieger et al., 1997) . These may contribute to the higher HbA1c in individuals with more severe OSA during REM sleep (Grimaldi et al., 2014) . The degree of OSArelated hypoxia is worsened by excess body weight (Peppard et al., 2009) . Specifically, increased body mass index (BMI) is a significant predictor of the severity of oxygen desaturation during OSA events, particularly during REM versus NREM sleep (Peppard et al., 2009) .
Look AHEAD (Action for Health in Diabetes) is a multicentre randomized clinical trial (n = 5145) to determine the effects of an intensive lifestyle intervention (ILI) targeted to weight loss on cardiovascular morbidity and mortality in overweight/obese T2D patients (Ryan et al., 2003) . In the complete Look AHEAD trial sample, the ILI, consisting of decreased caloric intake and increased physical activity, induced significant and sustained reductions in body weight and HbA1c compared to the diabetes support and education (DSE) control group (Wing et al., 2013) . Results from the ancillary Sleep AHEAD study demonstrated that ILI was also associated with reduced OSA severity, quantified as a decrease in the apnea-hypopnea index (AHI) compared to DSE (Kuna et al., 2013) . Both body weight loss and intervention group were significant predictors of reduced AHI during the 4-year follow-up (Kuna et al., 2013) . It is unknown if OSA severity during REM sleep in particular is improved by the ILI. Furthermore, it is unknown if REM sleep AHI is related to longitudinal changes in glycaemic control within this cohort.
The first aim of the study was to determine if ILI versus DSE results in a reduction of REM sleep-related AHI (REM-AHI). If so, this could present an added health benefit of the multi-component behavioural lifestyle intervention. The second aim was to determine if longitudinal changes in REM-AHI are related to concurrent improvements in glycaemic control during a 4-year follow-up period. As the lifestyle intervention improves HbA1c, the current analysis presents an opportunity to investigate a potential mechanism linking improvements in sleep and/or body weight to glycaemic control. We hypothesized that ILI versus DSE would result in significantly reduced REM-AHI. Based on the relationship between REM sleep-related OSA and glycaemic control (Grimaldi et al., 2014) , we hypothesize that a reduction in REM-AHI during the 4-year follow-up period would be related to improvements in HbA1c over time, after controlling for potential baseline and time-varying confounders.
METH ODS Participants
Participants were enrolled in Sleep AHEAD, a four-centre ancillary study of the Look AHEAD trial. Look AHEAD is a 16-centre randomized-controlled trial (RCT) to investigate the long-term effects of ILI on cardiovascular morbidity and mortality in overweight/obese T2D patients (Bray et al., 2006; Ryan et al., 2003) . Primary inclusion criteria for Look AHEAD were aged 45-76 years, physician-verified presence of T2D, HbA1c < 11%, BMI ≥ 25 kg m 2 or ≥ 27 kg m 2 if taking insulin, and blood pressure < 160/100 mmHg. Inclusion criteria for Sleep AHEAD included all primary inclusion criteria for the Look AHEAD trial and some further sleep-related items. Only those Sleep AHEAD participants with OSA at baseline (AHI ≥ 5 events h À1 ) were included in the current analysis (264 of 306 participants). Central apnea was exclusionary. In the initial design of the Sleep AHEAD protocol, it was decided that the primary analysis would focus on individuals with OSA at baseline, defined as AHI ≥ 5 events h À1 , as the main group of interest. Individuals with AHI <5 events h À1 at baseline had a less complete and thorough follow-up, and are not included in these analyses. Use of continuous positive airway pressure (CPAP) during the follow-up was not exclusionary for enrolment in the Sleep AHEAD trial. As described in prior Sleep AHEAD publications, participants refrained from CPAP for three nights preceding the study, as this duration is sufficient to reverse CPAP-related effects on AHI (Kohler et al., 2011) . However, CPAP use may have affected HbA1c levels (a primary outcome), and refraining from CPAP for 3 days is unlikely to reverse these effects. Accordingly, a separate analysis was completed after excluding participants who used CPAP, as was performed by others (Young et al., 2008) . A total of 42 participants used CPAP at some point during follow-up. All participants provided written informed consent, and experimental procedures, including administering the interventions and obtaining measures, were approved by the Institutional Review Board of each of the four centres participating as Sleep AHEAD sites (University of Pennsylvania; University of Pittsburgh; St Luke's-Roosevelt Hospital/Columbia University; and The Miriam Hospital/Brown University).
Intervention
Look AHEAD design and intervention have been described (Ryan et al., 2003) . Briefly, participants were allocated randomly to either ILI or DSE. ILI was a group behavioural weight loss programme developed for overweight/obese T2D patients, consisting of reduced daily caloric intake and increased physical activity (Kuna et al., 2013; Ryan et al., 2003) . Daily caloric intake was 1200-1500 kcal for individuals < 113.6 kg and 1500-1800 kcal for those with body weight > 113.6 kg. The physical activity component consisted of 175 min week À1 of moderate intensity activity. In ª 2017 European Sleep Research Society DSE, participants were provided with three group support and education sessions per year, focusing on diet and physical activity education, and social support. There were no specific behaviour change strategies. Technical staff involved in the sleep studies and scoring of polysomnographic (PSG) recordings remained blinded to the randomization.
Measures
Unattended overnight PSG using a portable system were obtained at baseline and at years 1, 2 and 4 follow-ups, as described previously (Foster et al., 2009a; Kuna et al., 2013; Shechter et al., 2014) . Recorded signals included electroencephalogram (EEG) (C3-A2 and C4-A1), bilateral electro-oculogram (EOG), chin electromyogram (EMG), electrocardiogram (ECG), rib cage and abdominal excursion, airflow via oronasal thermistry and nasal pressure cannula and oxygen saturation via pulse oximetry. Recordings were scored at a single reading laboratory using recommended criteria (Kushida et al., 2005) . Total sleep time (TST) was the sum of the duration of stages 1 and 2, slow wave sleep (SWS) and REM sleep. Time in NREM sleep was the sum of the duration of stages 1 and 2 and SWS. Apnea was defined as the cessation of airflow ≥ 10 s with concomitant respiratory-related chest wall movement for obstructive apnea or in the absence of respiratory related chest wall movement for central apnea. Hypopnea was defined as ≥ 30% reduction in airflow or thoraco-abdominal movement for ≥ 10 s with ≥ 4% oxygen desaturation. Total AHI was the sum of the number of apneas and hypopneas per hour of sleep. REM-AHI was the sum of the number of apneas and hypopneas occurring during REM sleep, expressed per hour of REM sleep. NREM-AHI was the sum of the number of apneas and hypopneas occurring during NREM sleep, expressed per hour of NREM sleep. In the first analysis, no minimum duration of REM sleep was used in the calculation of REM-AHI. However, in a secondary analysis, a minimum REM sleep duration threshold of 30 min was used as a requirement to calculate REM-AHI (Mokhlesi and Punjabi, 2012) . Intrascorer reliability across the 4-year follow-up was assessed and confirmed (Shechter et al., 2014) . Height and weight were assessed at clinic visits within 1 week of PSG, and used to calculate BMI (kg m
À2
). Fasting blood samples were obtained and assayed for HbA1c at annual clinic visits (Ryan et al., 2003) .
Statistical analyses
Analyses were conducted to determine if missing follow-up data could potentially bias the results. These were described in detail in a prior publication (Kuna et al., 2013) . Using generalized estimating equation models, the probability of a missing PSG was not related to baseline AHI, intervention arm or follow-up weight measurements (Kuna et al., 2013) . Furthermore, in pattern-mixture models, missing data patterns, either as a main effect or as moderated by intervention arm or year, were not related to observed changes in AHI (Kuna et al., 2013) .
Adjusted change-from-baseline was calculated for NREM-AHI and REM-AHI at years 1, 2 and 4. Changes-frombaseline for these parameters were adjusted for age, sex, race, baseline BMI and site. Repeated-measure linear-mixed model analysis was used to determine the between-group differences in adjusted NREM-AHI and REM-AHI changefrom-baseline to years 1, 2 and 4. This analysis was also performed after adjustment for body weight change over time to determine how weight change affects between-group differences in NREM-AHI and REM-AHI. Repeated-measure mixed-model analyses were used to assess the relationship between changes in OSA (NREM-AHI, REM-AHI) over time and changes in HbA1c at years 1, 2 and 4 when data from all participants were pooled together. For the mixed-model analyses, individuals without baseline were excluded. Dependent variables were changes-from-baseline in HbA1c at years 1, 2 and 4. Predictor variables for the models were group (ILI versus DSE), year, baseline REM-AHI or NREM-AHI and change in REM-AHI or NREM-AHI. An additional analysis was performed by adding baseline body weight and change in body weight to the model as predictor variables to determine whether REM-AHI and NREM-AHI contribute to predicted changes in HbA1c after adjusting for the effects of weight loss. A treatment group 9 year interaction was also included in the models. The reference level for the predictor 'group' was DSE and for the predictor 'year' was year 4. Models were adjusted for relevant covariates including age, sex, race, baseline BMI, site and baseline AHI and HbA1c. Analyses were repeated after excluding participants who used CPAP at any time-point during the trial and those who did not reach the minimum REM sleep duration threshold of 30 min.
RESULTS
In the Sleep AHEAD trial, 264 participants with OSA were included. Baseline characteristics, including demographics, anthropometry, OSA severity, sleep duration and architecture (TST, stages 1 and 2, SWS, REM sleep) and HbA1c have been reported previously (Kuna et al., 2013; Shechter et al., 2014) . No baseline between-group differences were observed. As reported (Kuna et al., 2013) , of the 264 participants, 125 were enrolled in ILI and 139 were enrolled in DSE at baseline. At year 1, 103 (82%) of those in ILI and 116 (83%) of those in DSE returned for follow-up. At year 2, 99 (79%) returned for ILI and 111 (80%) returned for DSE. Patients returning for follow-up at year 4 included 82 (66%) for ILI and 83 (60%) for DSE. Table 1 contains participant characteristics at baseline for all Sleep AHEAD participants (top panel; n = 264) and after excluding for CPAP use and minimum REM sleep duration (n = 192, bottom panel) . No between-group differences at baseline were observed for AHI-total, NREM-AHI or REM-AHI (P-values ≥ 0.75). In all participants at baseline, ª 2017 European Sleep Research Society regardless of treatment arm, AHI was significantly higher in REM sleep versus NREM sleep (P < 0.001). Table 2 presents the estimated mean changes in REM-AHI and NREM-AHI from baseline to years 1, 2 and 4, without adjustment for changes in weight over time. When considering all participants, significant between-group treatment differences in REM-AHI were observed at each year, with REM-AHI more reduced in ILI versus DSE at each follow-up. Between-group comparisons revealed significantly reduced NREM-AHI in ILI versus DSE at years 1, 2 and 4 follow-ups. When participants using CPAP or not reaching the REM sleep duration threshold were excluded the results were the same as above, except that year 1 between-group differences in NREM-AHI were no longer significant (Table 2) . Table 2 also presents the estimated mean changes in REM-AHI and NREM-AHI from baseline to years 1, 2 and 4 after adjustment for weight change over time. Values of REM-AHI remained more reduced in ILI versus DSE at each followup. Between-group differences were of a smaller magnitude than non-weight loss adjusted differences, and showed statistically significant differences at only years 1 and 2, but not year 4. Values of NREM-AHI also remained more reduced in ILI versus DSE at each follow-up, but were of smaller magnitude than non-weight loss adjusted differences, and were only statistically significantly different at year 2. When participants using CPAP or not reaching the REM sleep duration threshold were excluded results were the same as above, except that year 4 between-group differences in REM-AHI were statistically significant ( Table 2) .
The relationships between changes in REM-AHI and HbA1c during years 1, 2 and 4, with and without inclusion of weight change over time, are presented in Table 3 . Changes in REM-AHI were not associated with changes in HbA1c, regardless of whether or not weight loss was included in the model. When weight changes were not included in the models, significant group 9 year interactions were observed, indicating that the pattern of change in HbA1c from baseline was significantly different (more reduced) in ILI versus DSE throughout the follow-up. When weight changes were included in the models, weight loss was a significant predictor of reduced HbA1c. Results were similar after excluding for CPAP use and REM sleep duration threshold, except that the ILI 9 year 2 interaction was no longer significant. Change in body weight remained the most important predictor of change in HbA1c.
The relationships between changes in NREM-AHI and HbA1c during years 1, 2 and 4, with and without inclusion of weight change over time, are presented in Table 4 . Changes in NREM-AHI were not associated with changes in HbA1c, regardless of whether or not weight loss was included in the model. When weight changes were not included in the models, significant group 9 year interactions were observed, indicating that the pattern of change in HbA1c from baseline was significantly different (more reduced) in ILI versus DSE during the follow-up. When included, change in body weight was again a significant predictor of change in HbA1c for all participants and after excluding for CPAP use and REM sleep threshold.
DISCUSSION
We report an improvement in REM-AHI after weight loss in patients with obesity, T2D and OSA. After controlling for confounding variables, REM-AHI and NREM-AHI were reduced in the ILI versus DSE. Improvements in AHI during REM or NREM sleep were not related to changes in HbA1c. Rather, participation in the ILI and, more importantly, weight loss, similar to Look AHEAD participants overall (Wing et al., 2013) , was found to improve HbA1c during the 4-year followup. Weight loss and other beneficial effects of the multicomponent ILI seem to improve HbA1c, as opposed to being caused directly by improvements in REM or NREM-AHI.
RCTs utilizing ILIs via low caloric intake (Johansson et al., 2009; Tuomilehto et al., 2009) or a combination of diet and physical activity (Foster et al., 2009b) explored how targeted weight loss affects AHI. These RCTs, similar to baseline- (Araghi et al., 2013) . However, none of the controlled or prospective intervention studies have described the effects of lifestyle intervention and weight loss on REM-AHI in addition to total AHI. REM-AHI appears to be a relevant, but often overlooked, clinical outcome which increases the risk for adverse cardiometabolic parameters (Kendzerska and Ayas, 2015) . REM sleep is associated with increases in heart rate, blood pressure, blood pressure variability and sympathetic nerve activity (Somers et al., 1993) . Apnea events are of longer duration and are associated with a greater degree of hypoxaemia in REM versus NREM sleep (Findley et al., 1985; Muraki et al., 2008; Series et al., 1990 ). Significant longitudinal relationships were found for REM-AHI with hypertension development and the risk of developing nocturnal non-dipping blood pressure (Mokhlesi et al., 2015) . We report that AHI was worse in REM versus NREM sleep and, accordingly, patients were at a high risk for the aforementioned consequences of REM-related OSA. Thus, the reduction of REM-AHI we observed after ILI presents a new beneficial result of the intervention.
The prevalence of OSA in T2D is approximately 71% (Pamidi and Tasali, 2012) . Studies investigating the relationship between OSA and glycaemic control in T2D have been inconsistent, with some showing a significant association between total AHI and HbA1c (Aronsohn et al., 2010; Grimaldi et al., 2014) , while others did not (Einhorn et al., 2007; Lam et al., 2010) . In a large group of participants, including those with normal glucose tolerance, impaired glucose tolerance, and T2D, HbA1c was significantly higher in those with AHI ≥ 30 versus those with AHI < 5 (Tamura et al., 2012) . However, when considering only those with T2D, no relationships were seen between AHI and HbA1c (Tamura et al., 2012) . In the large European Sleep Apnea Cohort study (n = 6616), not only was T2D prevalence increased with greater severity of OSA, but within individuals with T2D increasing OSA severity predicted worsened glycaemic control (Kent et al., 2014) . Together, this implies that the relationship between OSA and glucose homeostasis is complex. In a recent study, REM-AHI but not NREM-AHI was related to HbA1c, with a statistically and clinically significant increase in HbA1c between the lowest and highest quartiles of REM-AHI (Grimaldi et al., 2014) . The crosssectional nature of their investigation lacks the ability to infer causality within the relationship (Grimaldi et al., 2014) . Our current longitudinal analyses further explored, within a controlled intervention, how OSA during REM sleep affects HbA1c. To our knowledge, this is the first investigation of the relationship between longitudinal changes in REM-AHI and HbA1c. Contrary to our hypothesis, longitudinal improvements in REM-AHI were not related to changes in HbA1c. Rather, we observed that participation in ILI and weight loss were associated with improvements in HbA1c, independent of changes in OSA severity.
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Participants after excluding for minimum REM sleep duration and CPAP use at follow-up (n = 192)
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Values are adjusted mean change from baseline (standard error) at years 1, 2 and 4. Analyses are adjusted for age, sex, race, baseline body mass index and site, and were performed with and without adjustment for body weight change over time. AHI: apnea-hypopnea index; CPAP: continuous positive airway pressure; DSE: diabetes support and education; ILI: intensive lifestyle intervention; NREM: non-rapid eye movement; REM: rapid eye movement. Statistically significant P-values (< 0.05) are shown in bold type.
ª 2017 European Sleep Research Society have been positive (Hassaballa et al., 2005; Shpirer et al., 2012; Steiropoulos et al., 2009) , others (Craig et al., 2012; West et al., 2007) have shown no effect of CPAP use on HbA1c. The inconsistent results were highlighted by two recent RCTs which appeared simultaneously in the same journal, and demonstrated either an improvement in HbA1c after 6 months of CPAP treatment (Mart ınez-Cer on et al., 2016) or no effect of CPAP on glycaemic control (Shaw et al., 2016) . The results of a recent meta-analysis of RCTs (although not including the aforementioned pair of studies) and prospective observational studies on the effects of CPAP on HbA1c in patients with OSA and T2D concluded that CPAP does not alter HbA1c (Feng et al., 2015) . Moreover, CPAP does not appear to reduce body weight, and may in fact lead to weight gain (Drager et al., 2015) . Together with our current findings, this suggests that a reduction in AHI, as is achieved with CPAP, is not sufficient to improve glycaemic control. Conversely, Grimaldi et al. (2014) suggested that insufficient CPAP use, which would fail to alleviate REM-related OSA events in the latter portion of the sleep episode, may explain the lack of an effect of CPAP on HbA1c. They propose that CPAP use of more than 6 h per night would be needed to achieve a significant improvement in glycaemic control. Current findings indicate alternatively that a significant reduction in nocturnal REM-AHI can be achieved by the ILI and/or weight loss, and that such lifestyle interventions targeting weight loss can reduce HbA1c. Our data suggest that a lifestyle intervention can be an effective and useful adjunctive to CPAP in the clinical care of T2D patients with OSA. Despite our findings, it is important to consider the relatively modest effects of the lifestyle intervention on REM-AHI within the proper context. While we observed statistically significant reductions in REM-AHI, the mean treatment-related reduction of~12 events h À1 (from a baseline value of~40 events h À1 )
is expected to leave a considerable amount of REM-AHI. It has been suggested that insufficient CPAP use may account for the lack of observed effects of CPAP on various cardiometabolic outcomes, including HbA1c, reported in some trials (Grimaldi et al., 2014; Pamidi et al., 2015) . It is possible that a complete alleviation of REM sleep-related OSA, which we were not able to demonstrate here, would have a more appreciable effect on improving glycaemic control in individuals with OSA and T2D. More work should therefore be conducted to determine this. The current strengths of this study are that we utilized data from a multi-centre RCT with a 4-year follow-up. The effects of intervention REM and NREM-AHI were not described in the prior interventions, which demonstrated an association between weight loss and improved AHI. Despite the large baseline sample size, 63% of participants returned at year 4. This high dropout rate (~37%), due probably to the added burden asked of Look AHEAD participants to undergo additional PSG recordings, should be emphasized as a limitation in the study. However, the probability of missing PSG was not related to baseline AHI, treatment group or follow-up body weight, and patterns of missing data were not related to observed change in AHI. Moreover, even with dropouts, the sample size remained larger than all prior lifestyle intervention trials investigating the relationship between weight loss and OSA severity (Johansson et al., 2009; Tuomilehto et al., 2009) . Sleep data were collected from single overnight recordings at each time-point, and the lack of an acclimatization night may affect recorded sleep quality. However, the at-home nature of the recording may mitigate some of the possible 'first-night effect'. As our study included only T2D participants, it is unclear if results can be extended to individuals with prediabetes aiming to improve
HbA1c. An additional limitation is that the analysis included only individuals who demonstrated some degree of OSA at baseline, based on a total AHI ≥ 5 events h À1 . It is possible that in focusing on these individuals we may have missed some participants who have clinically relevant REM sleeprelated OSA, despite not achieving minimum requirements for a standard OSA diagnosis (Mokhlesi and Punjabi, 2012) . We observed that the ILI for weight loss was successful in reducing AHI during REM and NREM sleep versus control in a large group of overweight/obese individuals with T2D and OSA. Weight loss, and not reduced REM-AHI, was associated with improved HbA1c. It should be emphasized that the initial Sleep AHEAD study was designed primarily to assess the effects of weight loss via an intensive lifestyle intervention on OSA severity in overweight and obese individuals with T2D (Foster et al., 2009a; Kuna et al., 2013) . The current post-hoc analysis reported here was concerned with two main questions not addressed in the initial reports: (1) the effects of weight loss induced by the intensive lifestyle intervention on REM sleep-related AHI and (2) the potential relationship between longitudinal changes in REM sleep-related AHI and improvements in glycaemic control. The current study was therefore not designed specifically to address the latter 
